RBC Capital Maintains QuidelOrtho(QDEL.US) With Buy Rating, Raises Target Price to $62
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
QuidelOrtho Raised to Neutral From Sell by UBS
RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating
QuidelOrtho Analyst Ratings
Craig-Hallum Upgrades QuidelOrtho(QDEL.US) to Buy Rating, Raises Target Price to $57
QuidelOrtho Analyst Ratings
RBC Capital Maintains QuidelOrtho(QDEL.US) With Buy Rating, Maintains Target Price $61
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
QuidelOrtho Analyst Ratings
Craig-Hallum Maintains QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $40
RBC Capital Maintains QuidelOrtho(QDEL.US) With Buy Rating, Maintains Target Price $61
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
Craig-Hallum Maintains QuidelOrtho(QDEL.US) With Hold Rating
Craig-Hallum Reaffirms Their Hold Rating on QuidelOrtho (QDEL)
RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating
QuidelOrtho Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Ligand Pharma (LGND) and Bioventus (BVS)
RBC Capital Remains a Buy on QuidelOrtho (QDEL)